https://pharmaphorum.com/r-d/breaking-into-the-global-制药-market-rudacure/
RudaCure is a four-year-old 生物科技公司 based in the 韩国, focusing on 眼部 disease and 慢性疼痛 with a pair of potentially first-in-class drugs. The company recently raised $16.5 million in Series A funding and has partnered with 翰林制药s, a local pharma company, to develop and distribute its 候选药物 for 干眼症.
The company recently incorporated in 美国 and is participating in a MassChallenge accelerator programme via a partnership between MassChallenge, 韩国’s Bio I-Corps programme and the 韩国 Innovation Center in 华盛顿. They’ve also begun attending US-based events like JP Morgan, to start to make the connections that will help them sell and develop their products on a global scale.
